Rett syndrome (RTT) is an X-linked neurodevelopmental disorder characterized by developmental regression with loss of motor, communication and social skills, onset of stereotypic hand movements and often seizures. RTT is primarily caused by de novo mutations in the methyl-CpG-binding protein 2 gene (MECP2). We established a high-resolution melting (HRM) technique for mutation scanning of the MECP2 gene and performed analyses in Czech patients with RTT, autism spectrum conditions and intellectual disability with Rett-like features. In the cases with confirmed MECP2 mutations, we determined X-chromosome inactivation (XCI), examined the relationships between genotype and clinical severity and evaluated the modifying influence of XCI. Our results demonstrate that HRM analysis is a reliable method for the detection of point mutations, small deletions and duplications in the MECP2 gene. We identified 29 pathogenic mutations in 75 girls, including four novel mutations: c.155_1189del1035;909_932inv;insC, c.573delC, c.857_858dupAA and c.1163_1200del38. Skewed XCI (ratio >75%) was found in 19.3% of the girls, but no gross divergence in clinical severity was observed. Our findings confirm a high mutation frequency in classic RTT (92%) and a correlation between the MECP2 mutation type and clinical severity. We also demonstrate limitations of XCI in explaining all of the phenotypic differences in RTT.

Department of Medical Genetics Thomayer Hospital Prague Czech Republic

Department of Pediatrics and Adolescent Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

See more in PubMed

Brain Dev. 2001 Dec;23 Suppl 1:S161-4 PubMed

Biosci Rep. 2011 Oct;31(5):333-43 PubMed

Blood Cells Mol Dis. 1998 Dec;24(4):439-47 PubMed

Hum Mutat. 2015 Dec;36(12):1197-204 PubMed

Neurology. 2009 Apr 7;72(14):1242-7 PubMed

Res Dev Disabil. 2014 Nov;35(11):2976-86 PubMed

Nucleic Acids Res. 2004 Mar 19;32(5):1818-23 PubMed

Eur J Hum Genet. 2013 Mar;21(3):266-73 PubMed

Am J Med Genet A. 2015 Sep;167A(9):2017-25 PubMed

Front Cell Neurosci. 2015 Jul 14;9:266 PubMed

Hum Genet. 2014 Jan;133(1):1-9 PubMed

Hum Mutat. 2001 Aug;18(2):132-40 PubMed

Gene. 2013 Feb 15;515(1):78-83 PubMed

Cell Rep. 2015 Sep 22;12(11):1887-901 PubMed

Science. 2008 May 30;320(5880):1224-9 PubMed

Methods. 2010 Apr;50(4):250-61 PubMed

J Med Genet. 2010 Jan;47(1):49-53 PubMed

Nucleic Acids Res. 1988 Feb 11;16(3):1215 PubMed

Am J Hum Genet. 2008 Jul;83(1):89-93 PubMed

Nat Genet. 2004 Apr;36(4):339-41 PubMed

Am J Hum Genet. 2004 Dec;75(6):1149-54 PubMed

J Med Genet. 2003 May;40(5):e52 PubMed

Nat Neurosci. 2013 Jul;16(7):898-902 PubMed

Nature. 2013 Jul 18;499(7458):341-5 PubMed

J Med Genet. 2014 Nov;51(11):724-36 PubMed

Am J Med Genet A. 2012 Feb;158A(2):340-50 PubMed

Ann Neurol. 2010 Dec;68(6):951-5 PubMed

J Biol Chem. 2003 Aug 22;278(34):32181-8 PubMed

Nat Genet. 1999 Oct;23(2):185-8 PubMed

Am J Hum Genet. 2004 Dec;75(6):1079-93 PubMed

Am J Hum Genet. 1999 Dec;65(6):1520-9 PubMed

Neurology. 2008 Apr 15;70(16):1313-21 PubMed

Ann Neurol. 2010 Dec;68(6):944-50 PubMed

J Child Neurol. 2010 May;25(5):546-50 PubMed

Am J Hum Genet. 2000 Dec;67(6):1428-36 PubMed

Blood Cells Mol Dis. 2015 Feb;54(2):210-6 PubMed

Hum Mutat. 2003 May;21(5):466-72 PubMed

Neurology. 2008 Mar 11;70(11):868-75 PubMed

Am J Hum Genet. 1992 Dec;51(6):1229-39 PubMed

J Hum Genet. 2007;52(4):342-8 PubMed

J Pediatr. 2006 Mar;148(3):347-52 PubMed

Cell. 2012 Dec 21;151(7):1417-30 PubMed

Clin Chem. 2003 Jun;49(6 Pt 1):853-60 PubMed

J Med Genet. 2014 Mar;51(3):152-8 PubMed

Eur J Hum Genet. 2002 Aug;10(8):487-90 PubMed

Nature. 1998 May 28;393(6683):386-9 PubMed

J Hum Genet. 2011 Jul;56(7):508-15 PubMed

Eur J Hum Genet. 2001 Mar;9(3):231-6 PubMed

J Child Neurol. 2007 Dec;22(12):1338-41 PubMed

Am J Med Genet A. 2004 Apr 15;126A(2):129-40 PubMed